At a glance
ClinicalIndex Comparison RecordN/ACompleted· 28 enrolled
Drug / intervention
Prostate Artery Embolizationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
In Brief
A clinical study evaluating Prostate Artery Embolization for Benign Prostatic Hyperplasia (BPH). Completed, enrolled 28 participants across 1 site.
Detailed Summary
This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia (BPH)
CountriesUnited States
CollaboratorsBTG International Inc.
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartSep 2017
Primary CompletionSep 2022
TodayJul 2026
First PostedFeb 14, 2017
Enrollment StartSep 6, 2017
Primary CompletionSep 26, 2022
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.4 years ago
Interventions
Prostate Artery Embolizationdevice
The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.